Investigational drug · Phase 2
AZD2811
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Small-Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "AZD2811"
First trial start
2021
Feb 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD2811", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small-Cell Lung Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD2811" as an intervention, largest first.
- A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.Completed
AstraZenecaAstraZeneca (AZN)
NCT02579226 · 72 participants · Start Oct 28, 2015 · Primary completion Feb 7, 2020
Drug: AZD2811 · For: Advanced Solid Tumours
Sites: Denver, Colorado; Sarasota, Florida; Boston, Massachusetts · 6 sites in all
AstraZenecaAstraZeneca (AZN)
NCT03217838 · 50 participants · Start Jul 31, 2017 · Primary completion Mar 25, 2021
Drug: AZD2811; Azacitidine and 1 more · For: Acute Myeloid Leukaemia
Sites: Denver, Colorado; Sarasota, Florida; Detroit, Michigan · 11 sites in all
- Study of AZD2811 + Durvalumab in ES-SCLCActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04745689 · 31 participants · Start Feb 23, 2021 · Primary completion Jun 18, 2022
Drug: Durvalumab; AZD2811 and 3 more · For: Small-Cell Lung Cancer
Sites: Grand Rapids, Michigan; Bydgoszcz, Poland; Olsztyn, Poland · 12 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT03366675 · 15 participants · Start Dec 1, 2017 · Primary completion Oct 8, 2018
Drug: AZD2811 · For: Small Cell Lung Cancer
Sites: Seoul, South Korea
Se-Hoon LeeAcademic, hospital or other
NCT04525391 · 4 participants · Start Sep 18, 2020 · Primary completion Jan 14, 2022
Drug: Durvalumab+AZD2811 to SCLC patients · For: SCLC, Recurrent
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives.
Karnik M, Anantharaju PG, Sharma A, et al. · Front Oncol 2026
- Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma.
Yun JH, Yoo S, Noh Y, et al. · Anticancer Res 2026
- Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.
Johnson ML, Fabbri G, Ciardullo C, et al. · Br J Cancer 2026
- Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells.
Duan L, O'Hara KM, Caldemeyer A, et al. · Mol Cancer Ther 2025
- High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma.
Gelb T, Garman KA, Urban D, et al. · Nat Commun 2025
- 1H-19F cross-polarization magic angle spinning dynamic nuclear polarization NMR investigation of advanced pharmaceutical formulations.
oltésová M, Pinon AC, Aussenac F, et al. · J Magn Reson 2025
Also in development for Small-Cell Lung Cancer
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- GocatamigHPN328, MK-6070Phase 34 trials
Merck & Co. · Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer
- ZL-1310Phase 33 trials
Zai Lab (Shanghai) Co., Ltd. · Solid Tumors, Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- IparomlimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- TuvonralimabPhase 32 trials
Qilu Pharmaceutical Co., Ltd. · Small-cell Lung Cancer, Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.